Navigation Links
PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
Date:11/17/2010

BOSTON, Nov. 17, 2010 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.  The studies, which were conducted in-house by its early phase units worldwide, enrolled more than 3,000 patients.  Early phase studies conducted in targeted patient populations are designed to demonstrate early signals of safety and efficacy in investigational medicines.

"To avoid costly late stage development failures, the biopharmaceutical industry has placed increased emphasis on conducting more complex, sophisticated, and rigorous early phase research, including earlier patient studies, to better predict safety and efficacy as well as identify and select the most promising new compounds.  To assist clients in achieving these goals, PAREXEL provides access to numerous patient populations for early phase studies, including Proof-of-Concept studies," said Sy Pretorius, M.D., M.S., M.B.A., Corporate Vice President and Worldwide Head of Early Phase, PAREXEL.  "Reaching the milestone of successfully completing the 200th early phase patient study performed in-house by our units over the last three years demonstrates our leading ability to help biopharmaceutical companies generate better and faster go/no-go decisions about their compounds."

Over several years, PAREXEL's early phase experts have developed extensive global databases of patients for inclusion in Phase I patient and Proof-of-Concept studies.  The databases, which include more than 70 diverse patient populations, are complemented by the capabilities of dedicated call centers, recruitment specialists,
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Team completes world-first ocean observatory
2. University of Hawaii completes 3-year investigation of military munitions sea disposal site
3. Kornberg Associates
4. Architects Completes UC Riverside Stem Cell Core Facility Project
5. KINAXO Completes Financing Round to Enhance Biomarker Development
6. Pacific Biometrics Completes $4 Million Debt Financing
7. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
8. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. DOE Joint Genome Institute completes soybean genome
11. Arsenic early in treatment improves survival for leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Assistance Foundation (AHAF, www.ahaf.org ), a nonprofit organization ... vision diseases, announced today that it has awarded 21 ... are studying glaucoma and macular degeneration. The two ... the world. "AHAF is known for pinpointing ...
... connection between the sickle cell trait and sudden cardiac ... observed in black military recruits 25 years ago, a ... confirms this risk for these individuals during competitive sports. ... African Americans are tested at birth, affects approximately 8 ...
... plants that suck water, nutrients and information from other plants ... of California, Davis, have now shown that they can make ... parasite taps into the host. "We think that this ... of plant biology at UC Davis, who led the project. ...
Cached Biology News:American Health Assistance Foundation announces grants to advance promising vision research 2American Health Assistance Foundation announces grants to advance promising vision research 3American Health Assistance Foundation announces grants to advance promising vision research 4Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3Hitting back at 'wiretapping' parasite 2
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Calif., Feb. 24, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... American Journal of Clinical Pathology demonstrated the ... HPV-16 and HPV-18, two of the highest risk HPV genotypes causing ... for Advanced HPV Diagnostics) study, which involved more than 47,000 women, ...
... Reportlinker.com announces that a new market research report ... Propylene Oxide: 2010 World Market Outlook And Forecast ... The report analyzes worldwide markets for Propylene oxide, ... It provides the most complete and current analytical ...
... (OTC Bulletin Board: OMBP):  Omni Bio Pharmaceutical, Inc. ("Omni ... James Crapo will become its Chief Executive Officer.  The ... Crapo as a director in the near term.  Dr. ... Chief Executive Officer since its inception in March 2009, ...
Cached Biology Technology:Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 2Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer 3Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Omni Bio Pharmaceutical Realigns Management 2Omni Bio Pharmaceutical Realigns Management 3Omni Bio Pharmaceutical Realigns Management 4
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
... DCTD_HUMAN GI Number: 4503277 ... 20016 Description: FUNCTION: Supplies the ... ACTIVITY: dCMP + H 2 O ... SUBUNIT: Homohexamer. SIMILARITY: Belongs to the ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
adult...
Biology Products: